Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quilizumab in Refractory Chronic Spontaneous Urticaria
NCT01987947Phase 2Completed
- Sponsor
- Genentech
- Start
- Dec 2013
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in chronic spontaneous urticaria (CSU) comparing Quilizumab with Placebo (2 arms). Primary endpoints: Absolute change from baseline to Week 20 in the weekly itch score, Incidence & severity of adverse events at 30 weeks and 1 more. Started Dec 2013; status: completed.
02
Drugs
quilizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT01987947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01987947.